loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Emavusertib

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Emavusertib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Curis Enters into Agreement for Emavusertib Combination Study in Melanoma
    Curis Enters into Agreement for Emavusertib Combination Study in Melanoma

    05 Dec 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/curis-enters-into-agreement-for-emavusertib--pembrolizumab-combination-study-in-melanoma-302005577.html

    PR NEWSWIRE
    05 Dec 2023
    Share Share
    FDA lifts partial hold on Curis' PhI/II leukemia study as biotech raises $15M 
    FDA lifts partial hold on Curis' PhI/II leukemia study as biotech raises $15M 

    07 Jul 2023

    // Paul Schloesser ENDPTS

    https://endpts.com/fda-lifts-partial-hold-on-curis-phi-ii-leukemia-study-as-biotech-raises-15m/

    Paul Schloesser ENDPTS
    07 Jul 2023
    Share Share
    FDA Lifts Partial Clinical Hold on TakeAim Leukemia Trial Emavusertib in AML/MDS
    FDA Lifts Partial Clinical Hold on TakeAim Leukemia Trial Emavusertib in AML/MDS

    07 Jul 2023

    // ONCLIVE

    https://www.onclive.com/view/fda-lifts-partial-clinical-hold-on-takeaim-leukemia-trial-of-emavusertib-in-aml-mds

    ONCLIVE
    07 Jul 2023
    Share Share
    FDA puts Curis' leukemia trial on partial hold after patient death
    FDA puts Curis' leukemia trial on partial hold after patient death

    04 Apr 2023

    // Nick Paul Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/fda-puts-curis-leukemia-trial-partial-hold-after-patient-death-spurs-review-muscle

    Nick Paul Taylor FIERCE BIOTECH
    04 Apr 2023
    Share Share
    FDA lets biotech resume enrollment for part of phase 1/2 leukemia study
    FDA lets biotech resume enrollment for part of phase 1/2 leukemia study

    31 Aug 2022

    // Gabrielle Masson FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/fda-sparks-hope-curis-lets-biotech-resume-enrollment-part-phase-12-leukemia-study

    Gabrielle Masson FIERCEBIOTECH
    31 Aug 2022
    Share Share
    FDA lifts partial clinical hold on Curis lymphoma study
    FDA lifts partial clinical hold on Curis lymphoma study

    19 Aug 2022

    // Jim Cornall LABIOTECH

    https://www.labiotech.eu/trends-news/chris-lymphoma-study/

    Jim Cornall LABIOTECH
    19 Aug 2022
    Share Share